vs
Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $14.9M, roughly 1.3× EVERSPIN TECHNOLOGIES INC.). SCYNEXIS INC runs the higher net margin — 65.7% vs -2.0%, a 67.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 13.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 18.2%).
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
MRAM vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.9M | $18.6M |
| Net Profit | $-296.0K | $12.3M |
| Gross Margin | 52.7% | — |
| Operating Margin | 29.0% | 56.3% |
| Net Margin | -2.0% | 65.7% |
| Revenue YoY | 13.2% | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $-0.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.9M | — | ||
| Q4 25 | $14.8M | $18.6M | ||
| Q3 25 | $14.1M | $334.0K | ||
| Q2 25 | $13.2M | $1.4M | ||
| Q1 25 | $13.1M | $257.0K | ||
| Q4 24 | $13.2M | $977.0K | ||
| Q3 24 | $12.1M | $660.0K | ||
| Q2 24 | $10.6M | $736.0K |
| Q1 26 | $-296.0K | — | ||
| Q4 25 | $1.2M | $12.3M | ||
| Q3 25 | $54.0K | $-8.6M | ||
| Q2 25 | $-670.0K | $-6.9M | ||
| Q1 25 | $-1.2M | $-5.4M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $2.3M | $-2.8M | ||
| Q2 24 | $-2.5M | $-14.5M |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.3% | — | ||
| Q2 25 | 51.3% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.2% | — | ||
| Q2 24 | 49.0% | — |
| Q1 26 | 29.0% | — | ||
| Q4 25 | -7.2% | 56.3% | ||
| Q3 25 | -11.0% | -2516.5% | ||
| Q2 25 | -14.9% | -701.0% | ||
| Q1 25 | -14.7% | -3350.2% | ||
| Q4 24 | -11.8% | — | ||
| Q3 24 | -17.5% | -1563.6% | ||
| Q2 24 | -26.5% | -1255.0% |
| Q1 26 | -2.0% | — | ||
| Q4 25 | 8.1% | 65.7% | ||
| Q3 25 | 0.4% | -2572.2% | ||
| Q2 25 | -5.1% | -504.8% | ||
| Q1 25 | -8.9% | -2097.7% | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 18.8% | -425.5% | ||
| Q2 24 | -23.5% | -1964.4% |
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $0.05 | $0.25 | ||
| Q3 25 | $0.00 | $-0.17 | ||
| Q2 25 | $-0.03 | $-0.14 | ||
| Q1 25 | $-0.05 | $-0.11 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.10 | $-0.06 | ||
| Q2 24 | $-0.12 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.5M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.2M | $49.4M |
| Total Assets | $83.2M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.5M | — | ||
| Q4 25 | $44.5M | $40.0M | ||
| Q3 25 | $45.3M | $37.9M | ||
| Q2 25 | $45.0M | $44.8M | ||
| Q1 25 | $42.2M | $40.6M | ||
| Q4 24 | $42.1M | $59.3M | ||
| Q3 24 | $39.6M | $68.8M | ||
| Q2 24 | $36.8M | $73.0M |
| Q1 26 | $70.2M | — | ||
| Q4 25 | $68.9M | $49.4M | ||
| Q3 25 | $65.8M | $36.4M | ||
| Q2 25 | $64.1M | $44.5M | ||
| Q1 25 | $63.0M | $50.5M | ||
| Q4 24 | $62.6M | $55.1M | ||
| Q3 24 | $59.3M | $58.5M | ||
| Q2 24 | $55.4M | $60.4M |
| Q1 26 | $83.2M | — | ||
| Q4 25 | $84.6M | $59.0M | ||
| Q3 25 | $80.3M | $51.1M | ||
| Q2 25 | $78.9M | $60.7M | ||
| Q1 25 | $80.2M | $67.9M | ||
| Q4 24 | $77.8M | $90.6M | ||
| Q3 24 | $72.6M | $99.0M | ||
| Q2 24 | $64.6M | $107.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $570.0K | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $570.0K | — | ||
| Q4 25 | $2.6M | $18.4M | ||
| Q3 25 | $881.0K | $-8.7M | ||
| Q2 25 | $5.0M | $-7.5M | ||
| Q1 25 | $1.4M | $-7.5M | ||
| Q4 24 | $3.8M | $-24.0M | ||
| Q3 24 | $2.8M | $765.0K | ||
| Q2 24 | $1.7M | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-975.0K | — | ||
| Q3 25 | $543.0K | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $527.0K | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $1.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 22.9% | — | ||
| Q2 24 | 15.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 6.9% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.19× | 1.50× | ||
| Q3 25 | 16.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.16× | — | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
